Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic (PDF) Site License Enterprisewide Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas Bioseeker, June 2007, Pages: 430   Description     Table of Contents     Summary     Companies Mentioned        Enquire before Buying    Send to a Friend   In this triple analysis report the author has analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates. This extensive 430+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors. There are currently more than 400 antibody based drugs in development for the treatment of cancer. The author has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care. Drug targets and their associated antibodies have been analyzed by the author according to: - 34 Different molecular functions of target - 13 Major signaling pathways - Cancer stem cells - Conjugated antibodies - Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition - 31 Targeted cancer indications - Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures - Antibody therapeutic companies Customers who bought this item also bought Structure-Guided Drug Design: Rediscovering the Importance of Drug Structure for Drug Discovery Novel Targets in Drug Discovery Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC Antibody Drug Targets and Focus on Breast & Prostate Cancer Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas Kinases: Advanced Strategies and Multiple Targets for Drug Discovery Orphan Drugs Pipeline Analysis: Wider Incentives Encourage Orphan Drug R&D Antibody Drug Target Atlas in Oncology

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster